The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin

The combination of ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein (NPC1L1), and an HMG-CoA reductase inhibitor decreases cholesterol absorption and synthesis. In clinical trials, ezetimibe plus simvastatin produces greater LDL-cholesterol reductions than does monotherapy. The molecular mechanism for this enhanced efficacy has not been defined. Apolipoprotein B-100 (apoB-100) kinetics were determined in miniature pigs treated with ezetimibe (0.1 mg/kg/day), ezetimibe plus simvastatin (10 mg/kg/day), or placebo (n = 7/group). Ezetimibe decreased cholesterol absorption (−79%) and plasma phytosterols (−91%), which were not affected further by simvastatin. Ezetimibe increased plasma lathosterol (+65%), which was prevented by addition of simvastatin. The combination decreased total cholesterol (−35%) and LDL-cholesterol (−47%). VLDL apoB pool size decreased 26%, due to a 35% decrease in VLDL apoB production. LDL apoB pool size decreased 34% due to an 81% increase in the fractional catabolic rate, both of which were significantly greater than monotherapy. Combination treatment decreased hepatic microsomal cholesterol (−29%) and cholesteryl ester (−65%) and increased LDL receptor (LDLR) expression by 240%. The combination increased NPC1L1 expression in liver and intestine, consistent with increased SREBP2 expression. Ezetimibe plus simvastatin decreases VLDL and LDL apoB-100 concentrations through reduced VLDL production and upregulation of LDLR-mediated LDL clearance. The combination of ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein (NPC1L1), and an HMG-CoA reductase inhibitor decreases cholesterol absorption and synthesis. In clinical trials, ezetimibe plus simvastatin produces greater LDL-cholesterol reductions than does monotherapy. The molecular mechanism for this enhanced efficacy has not been defined. Apolipoprotein B-100 (apoB-100) kinetics were determined in miniature pigs treated with ezetimibe (0.1 mg/kg/day), ezetimibe plus simvastatin (10 mg/kg/day), or placebo (n = 7/group). Ezetimibe decreased cholesterol absorption (−79%) and plasma phytosterols (−91%), which were not affected further by simvastatin. Ezetimibe increased plasma lathosterol (+65%), which was prevented by addition of simvastatin. The combination decreased total cholesterol (−35%) and LDL-cholesterol (−47%). VLDL apoB pool size decreased 26%, due to a 35% decrease in VLDL apoB production. LDL apoB pool size decreased 34% due to an 81% increase in the fractional catabolic rate, both of which were significantly greater than monotherapy. Combination treatment decreased hepatic microsomal cholesterol (−29%) and cholesteryl ester (−65%) and increased LDL receptor (LDLR) expression by 240%. The combination increased NPC1L1 expression in liver and intestine, consistent with increased SREBP2 expression. Ezetimibe plus simvastatin decreases VLDL and LDL apoB-100 concentrations through reduced VLDL production and upregulation of LDLR-mediated LDL clearance. Increased concentrations of LDL-cholesterol represent a major risk factor for atherosclerosis (1Grundy S.M. Cleeman J.I. Merz C.N. Brewer H. B.J. Clark L.T. Hunninghake D.B. Pasternak R.C. Smith S. C.J. Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239Google Scholar, 2Genest J. Frohlich J. Fodor G. McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003; 169: 921-924Google Scholar). Clinical trials demonstrate that reduction of plasma LDL-cholesterol by diet and/or drugs constitutes a primary strategy for the prevention and regression of coronary heart disease (1Grundy S.M. Cleeman J.I. Merz C.N. Brewer H. B.J. Clark L.T. Hunninghake D.B. Pasternak R.C. Smith S. C.J. Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239Google Scholar, 2Genest J. Frohlich J. Fodor G. McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003; 169: 921-924Google Scholar). LDL concentrations are regulated primarily in the liver; it is the source of VLDL, the precursor of plasma LDL, and is responsible for the majority of LDL clearance via the LDL receptor (LDLR) (3Dietschy J.M. Turley S.D. Spady D.K. Role of the liver in the maintenance of cholesterol and low-density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 1993; 34: 1637-1659Google Scholar). Apolipoprotein B-100 (apo B-100) kinetic studies in patients with primary hypercholesterolemia and combined hyperlipidemia demonstrate that LDL-cholesterol concentrations are determined by the production and catabolism of LDL particles (4Kesaniemi Y.A. Beltz W.F. Grundy S.M. Comparisons of metabolism of apolipoprotein B in normal subjects, obese subjects and patients with coronary heart disease. J. Clin. Invest. 1985; 76: 586-595Google Scholar, 5Parhofer K.G. Barrett P.H. What we have learned about VLDL and LDL metabolism from human kinetic studies. J. Lipid Res. 2006; 47: 1620-1630Google Scholar). HMG-CoA reductase inhibitors (statins) decrease cholesterol synthesis primarily in the liver (3Dietschy J.M. Turley S.D. Spady D.K. Role of the liver in the maintenance of cholesterol and low-density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 1993; 34: 1637-1659Google Scholar), resulting in reduced hepatocyte cholesterol concentrations and, ultimately, upregulation of the LDLR and enhanced clearance of LDL (as reviewed in Ref. 6Ginsberg H.N. Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J. Clin. Endocrinol. Metab. 2006; 91: 383-392Google Scholar). In some patients, statins decrease rates of VLDL production (7Huff M.W. Burnett J.R. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr. Opin. Lipidol. Scholar). The liver cholesterol from the intestine, via of (3Dietschy J.M. Turley S.D. Spady D.K. Role of the liver in the maintenance of cholesterol and low-density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 1993; 34: 1637-1659Google Scholar, S.D. J.M. absorption by the Curr. Opin. Lipidol. 2003; Scholar). In of cholesterol the is of is from S.M. A for of hepatic of in Scholar). of cholesterol absorption a has with the of ezetimibe, the of a of cholesterol absorption inhibitors of the and of the cholesterol absorption and J. Scholar, Ezetimibe cholesterol absorption in in the and of J. Scholar, The of the cholesterol absorption ezetimibe, in combination with coenzyme A reductase inhibitors in Scholar, S. of cholesterol absorption by ezetimibe in humans. Circulation. Scholar). J. G. J. Niemann-Pick 1 is the and cholesterol and a of cholesterol J. 2004; Scholar, J. Burnett H. The of ezetimibe is Niemann-Pick 1 Scholar, H. G. Niemann-Pick 1 protein is for cholesterol 2004; has that ezetimibe the of cholesterol and phytosterols the of the by the of molecular Niemann-Pick 1 protein (NPC1L1), (as reviewed in Ref. and absorption are Ezetimibe cholesterol absorption in in the and of J. Scholar). cholesterol is in a reduction in cholesterol the liver via J. G. J. Niemann-Pick 1 is the and cholesterol and a of cholesterol J. 2004; Scholar, J. Burnett H. The of ezetimibe is Niemann-Pick 1 Scholar, H. G. Niemann-Pick 1 protein is for cholesterol 2004; Scholar, M.W. from to 2006; Scholar). hepatic cholesterol has been in J. G. J. Niemann-Pick 1 is the and cholesterol and a of cholesterol J. 2004; Scholar, Turley S.D. G. J.M. of molecular in cholesterol metabolism resulting from cholesterol J. Lipid Res. and The of the cholesterol absorption ezetimibe, in combination with coenzyme A reductase inhibitors in Scholar), and in in hepatic LDLR expression were Turley S.D. G. J.M. of molecular in cholesterol metabolism resulting from cholesterol J. Lipid Res. Scholar). it has not been determined the molecular mechanisms cholesterol homeostasis in the liver and in to ezetimibe the kinetics of apoB apoB-100 kinetic studies that in with primary ezetimibe decreased LDL-cholesterol primarily through enhanced fractional catabolic rates of VLDL, lipoprotein and LDL, upregulation of hepatic LDLR of ezetimibe the in kinetics of and apoB-100 in with primary 2006; Scholar). of cholesterol absorption in by ezetimibe to in cholesterol synthesis in and liver J. G. J. Niemann-Pick 1 is the and cholesterol and a of cholesterol J. 2004; Scholar, H. G. Niemann-Pick 1 protein is for cholesterol 2004; Scholar, Turley S.D. G. J.M. of molecular in cholesterol metabolism resulting from cholesterol J. Lipid Res. Scholar). this reductions in hepatic the of LDLR expression and the of LDL-cholesterol ezetimibe and a LDL-cholesterol through mechanisms of action S.D. J.M. absorption by the Curr. Opin. Lipidol. 2003; Scholar, for for cardiovascular risk J. Scholar). The combination LDL-cholesterol reductions in The of the cholesterol absorption ezetimibe, in combination with coenzyme A reductase inhibitors in Scholar), and in clinical trials, combination decreases LDL-cholesterol to a significantly greater than does J. R. S. of ezetimibe with in patients with primary a Circulation. 2003; Scholar, R. A to the efficacy and of the with ezetimibe and simvastatin in patients with primary Clin. 2004; Scholar). the mechanism this combination the kinetics of apoB metabolism has not been the of ezetimibe plus a the expression of for the of LDL metabolism in the liver and has not been defined. the of ezetimibe or in combination with simvastatin apoB-100 kinetics in miniature a of lipoprotein Ezetimibe plus simvastatin decreased VLDL and LDL apoB-100 ezetimibe cholesterol and simvastatin the increase in cholesterol synthesis with ezetimibe in reductions of hepatic cholesterol and a increase in hepatic LDLR expression. apoB decreased significantly through a reduction in VLDL production and a enhanced LDLR-mediated LDL both of which are to the reduction in hepatic pigs were in and were a diet 34% of from and of cholesterol The diet a human The of to to was by and J.R. Barrett M.W. of cholesterol by decreases hepatic apolipoprotein B in of and Scholar). were a and with to total plasma were to ezetimibe (0.1 or ezetimibe plus simvastatin (10 or placebo (n = 7/group). was through in J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar). The pigs were for to The was by the of the of Ezetimibe and simvastatin were from of were in and by In a (n = of ezetimibe and decreased cholesterol absorption by and and reduced LDL-cholesterol by and with In a J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar), we in this the that simvastatin a of decreased LDL-cholesterol by of simvastatin was it of the and kinetic J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature with in the with ezetimibe or in combination with simvastatin. ezetimibe (0.1 and simvastatin (10 were for the apoB kinetic studies. plasma and lipoprotein and of apoB have been J.R. Barrett M.W. of cholesterol by decreases hepatic apolipoprotein B in of and Scholar, J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar, J.R. Barrett M.W. of HMG-CoA reductase by decreases both VLDL and LDL apolipoprotein B production in miniature Scholar, J.R. Barrett M.W. of by decreases both VLDL and LDL apolipoprotein B production in miniature J. Lipid Res. Scholar, S.M. Barrett P.H. Burnett J.R. M.W. of both the and HMG-CoA reductase the clearance of LDL J. Lipid Res. 2003; Scholar). The of apoB in VLDL, and LDL was determined by and by J.R. Barrett M.W. of HMG-CoA reductase by decreases both VLDL and LDL apolipoprotein B production in miniature Scholar). cholesterol were in from pigs in that were by size a of LDL in of from and Scholar). lathosterol and concentrations were by Barrett P.H. of reductase inhibitor and apolipoprotein B-100 kinetics in obese subjects with dyslipidemia. Scholar). The plasma by and S.D. M.W. J.M. and of the plasma for the of cholesterol absorption in the J. Lipid Res. was for in The of and in were to in and in of The was to (0.1 for The was to for of were to of III and in a to of the in the or a pigs were J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature of by and of via the from the of ezetimibe, or ezetimibe plus simvastatin with the of The was for were via the to of plasma was to the and to that the plasma of the were The cholesterol absorption was from the plasma the plasma cholesterol absorption = of of a of via the a S.M. Barrett P.H. H. M.W. A inhibitor of low-density lipoprotein apolipoprotein production and low-density lipoprotein catabolism through reduction in hepatic cholesterol Scholar). were and VLDL, LDL, and were by was by and to Barrett P.H. of reductase inhibitor and apolipoprotein B-100 kinetics in obese subjects with dyslipidemia. Scholar). was to the and was determined by Barrett P.H. of reductase inhibitor and apolipoprotein B-100 kinetics in obese subjects with dyslipidemia. Scholar). of apoB-100 metabolism were to the S.M. Barrett P.H. H. M.W. A inhibitor of low-density lipoprotein apolipoprotein production and low-density lipoprotein catabolism through reduction in hepatic cholesterol Scholar). the of pigs were and of were and In liver and the concentrations of cholesterol and cholesteryl ester and the of and were S.M. Barrett P.H. Burnett J.R. M.W. of both the and HMG-CoA reductase the clearance of LDL J. Lipid Res. 2003; Scholar). and microsomal and HMG-CoA reductase were determined S.M. Barrett P.H. Burnett J.R. M.W. of both the and HMG-CoA reductase the clearance of LDL J. Lipid Res. 2003; Scholar). was for HMG-CoA and was by an to the S.M. Barrett P.H. H. M.W. A inhibitor of low-density lipoprotein apolipoprotein production and low-density lipoprotein catabolism through reduction in hepatic cholesterol Scholar). of total were in in a and the to for were to expression for with and and were S.M. Barrett P.H. H. M.W. A inhibitor of low-density lipoprotein apolipoprotein production and low-density lipoprotein catabolism through reduction in hepatic cholesterol Scholar). with and were the of the human The were that the was to and were with and liver or total the of were the and a A of of the to the human was for and were were from and the with were from and for are in 1 and in in the and of and ezetimibe plus miniature to to to with and and were with and were the of the human were with and liver or total the of were the and a A of of the to the human was for and were were from and the with were from in a with and and were with and were the of the human were with and liver or total the of were the and a A of of the to the human was for and were were from and the with were from and ezetimibe plus were for by was Ezetimibe reduced plasma total cholesterol and LDL-cholesterol 1 Ezetimibe plus simvastatin significantly greater reductions in both total and LDL-cholesterol with ezetimibe were Ezetimibe decreased VLDL apoB and LDL apoB The combination decreased VLDL apoB with ezetimibe the 34% reduction in LDL apoB was significantly greater than ezetimibe monotherapy. cholesterol absorption in pigs was to for W.F. cholesterol absorption in normal and with and J. Lipid Res. Scholar). Ezetimibe absorption and decreased plasma concentrations efficacy in pigs J. G. J. Niemann-Pick 1 is the and cholesterol and a of cholesterol J. 2004; Scholar, G. J. Ezetimibe plasma in patients with Circulation. 2004; Scholar). Ezetimibe plus simvastatin lathosterol a of cholesterol were increased by ezetimibe, the increase in cholesterol synthesis by concentrations decreased to with the addition of of hepatic cholesterol synthesis. The of plasma and lathosterol to the of plasma cholesterol are in The a of to of the concentrations of to of the was a kinetic were determined from of S.M. Barrett P.H. H. M.W. A inhibitor of low-density lipoprotein apolipoprotein production and low-density lipoprotein catabolism through reduction in hepatic cholesterol Scholar). A of VLDL and LDL apoB for of is in in the Ezetimibe significantly decreased VLDL apoB pool size this decrease was to a decrease in VLDL apoB production Ezetimibe plus simvastatin decreased the VLDL apoB pool size due to a 35% decrease in VLDL apoB production was significantly different from ezetimibe VLDL the of VLDL apoB to LDL and the from plasma were not apoB kinetic were not of VLDL and LDL apoB metabolism in and ezetimibe plus miniature size to the plasma VLDL apoB by plasma is determined by apoB pool is the production of VLDL and in to of the to size to the plasma LDL apoB by plasma is the determined from the production is the production of apoB plasma LDL, apoB apoB production is the production of apoB the plasma VLDL apoB production plus LDL apoB (0.1 (0.1 and simvastatin (10 apolipoprotein fractional catabolic was size to the plasma VLDL apoB by plasma is determined by apoB pool is the production of VLDL and in to of the size to the plasma LDL apoB by plasma is the determined from the production is the production of apoB plasma LDL, apoB production is the production of apoB the plasma VLDL apoB production plus LDL apoB production. in a apolipoprotein fractional catabolic was Ezetimibe significantly decreased the LDL apoB pool size due to a increase in the LDL apoB total LDL apoB production was The combination decreased the LDL apoB pool size 34% due to an 81% increase in the LDL apoB with ezetimibe the combination enhanced the decrease in pool size and increased the LDL apoB synthesis was apoB production plasma plus LDL decreased with ezetimibe and 35% with combination treatment VLDL and LDL were for and protein Ezetimibe decreases in the of cholesterol in VLDL the of increased were greater with combination Ezetimibe decreased the LDL of and increased the of and protein and were greater with combination were The in LDL increased reductions in VLDL and which were enhanced by the addition of simvastatin of cholesterol lipoprotein and the of to were by lipoprotein Ezetimibe decreased liver and and The combination significantly reduced hepatic and and reductions were not different from ezetimibe with liver were decreased by and by ezetimibe and the Ezetimibe decreased hepatic microsomal and The combination reduced hepatic microsomal and we that in pigs treated with simvastatin (10 mg/kg/day), liver microsomal and were J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar). Ezetimibe decreased liver and The combination reductions in both liver and with In the concentrations and and were by expression of in hepatic cholesterol metabolism was determined in liver and LDLR increased with ezetimibe, and increased further to with the combination were in the we that in pigs treated with simvastatin (10 mg/kg/day), liver and LDLR both increased J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar). for HMG-CoA reductase increased with ezetimibe, and increased further to with the combination HMG-CoA reductase increased in hepatic of pigs and increased in from the combination in and of HMG-CoA reductase were in the and NPC1L1 expression increased in and liver with ezetimibe The combination increased NPC1L1 expression in and liver to were not different from ezetimibe the expression of NPC1L1 in to liver was not the enhanced expression of NPC1L1 in liver the of cholesterol Ezetimibe increased SREBP2 in liver and in The combination increased SREBP2 in liver and in the intestine, with was significantly decreased by combination treatment in the including and were the major apoB-100 kinetic ezetimibe and ezetimibe plus simvastatin VLDL apoB pool size primarily of the reduced of VLDL apoB in LDL apoB concentrations primarily of an increased the from in apoB kinetic in the with determined in a simvastatin (10 J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar). the animal and the were in both the the to this have in some in of kinetic are and the combination decreased VLDL apoB pool size of decreased production. of simvastatin to ezetimibe not to Ezetimibe significantly reduced LDL pool to an increased In simvastatin decreased LDL apoB through decreased the in and hepatic LDLR were The addition of simvastatin to ezetimibe enhanced the reduction in LDL apoB pool of a increase in LDL apoB of cholesterol absorption by ezetimibe has the to decrease cholesterol to the liver via hepatic cholesterol expression of the resulting in decreased plasma hepatic cholesterol is by a increase in hepatic cholesterol the addition of an HMG-CoA reductase inhibitor an combination for LDL-cholesterol reduction through mechanisms of for the in a of lipoprotein metabolism the molecular mechanisms the reductions in both VLDL and LDL The combination of ezetimibe plus simvastatin decreased VLDL and LDL apoB-100 concentrations through reduced VLDL production and enhanced LDLR-mediated LDL clearance. Ezetimibe cholesterol and simvastatin the increase in cholesterol synthesis with ezetimibe resulting in a reduction in hepatic cholesterol and a increase in hepatic LDLR expression. we that expression of NPC1L1 in both and liver is increased with ezetimibe and combination consistent with by we reduced VLDL apoB in pigs treated with J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar, J.R. Barrett M.W. of HMG-CoA reductase by decreases both VLDL and LDL apolipoprotein B production in miniature Scholar), simvastatin J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar), or the inhibitor S.M. Barrett P.H. H. M.W. A inhibitor of low-density lipoprotein apolipoprotein production and low-density lipoprotein catabolism through reduction in hepatic cholesterol Scholar). VLDL apoB has been to decreased of cholesterol for hepatic lipoprotein (7Huff M.W. Burnett J.R. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr. Opin. Lipidol. Scholar, J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar, Turley S.D. J.M. hepatic cholesteryl ester and in the liver of the J. Lipid Res. Scholar). liver and in pigs treated with ezetimibe and ezetimibe plus simvastatin is consistent with this VLDL by hepatic which were reduced by ezetimibe monotherapy. The addition of simvastatin further decrease in liver cholesterol or consistent with studies in which simvastatin hepatic concentrations J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar). The reduction in hepatic has been in Turley S.D. G. J.M. of molecular in cholesterol metabolism resulting from cholesterol J. Lipid Res. and a cholesterol absorption combined dyslipidemia in obese Scholar), and that ezetimibe does not absorption Ezetimibe cholesterol absorption in in the and of J. Scholar), decreased hepatic is to and of hepatic The of decreased hepatic to the VLDL apoB is to studies in this have reductions in VLDL apoB which were with hepatic cholesterol hepatic synthesis and concentrations were J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar, J.R. Barrett M.W. of HMG-CoA reductase by decreases both VLDL and LDL apolipoprotein B production in miniature Scholar, S.M. Barrett P.H. Burnett J.R. M.W. of both the and HMG-CoA reductase the clearance of LDL J. Lipid Res. 2003; Scholar, S.M. Barrett P.H. H. M.W. A inhibitor of low-density lipoprotein apolipoprotein production and low-density lipoprotein catabolism through reduction in hepatic cholesterol Scholar). In patients treated with ezetimibe, of ezetimibe the in kinetics of and apoB-100 in with primary 2006; increased VLDL apoB production a decrease in VLDL apoB concentrations and increased VLDL apoB The for the increased production is the or the The efficacy of ezetimibe for LDL-cholesterol reduction in patients with hypercholesterolemia Efficacy and of ezetimibe with or simvastatin in patients with Circulation. Scholar), and in Turley S.D. G. J.M. of molecular in cholesterol metabolism resulting from cholesterol J. Lipid Res. Scholar), a for ezetimibe in hepatic VLDL production. Ezetimibe significantly decreased LDL apoB concentrations a of enhanced clearance of LDL apoB from consistent with the increase in hepatic LDLR was significantly by reductions in plasma LDL apoB and in hepatic LDLR LDL apoB clearance was in pigs treated with (10 J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar), was in pigs treated with a of J.R. Barrett M.W. of HMG-CoA reductase by decreases both VLDL and LDL apolipoprotein B production in miniature or simvastatin (10 J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar). In of the decreased LDL apoB a of in LDL apoB in and in combination with S.M. Barrett P.H. Burnett J.R. M.W. of both the and HMG-CoA reductase the clearance of LDL J. Lipid Res. 2003; Scholar, M.W. Burnett J.R. Barrett of the LDL cholesterol and apoB by enhanced plasma clearance of LDL Scholar), that drugs with mechanisms of action LDL apoB clearance. that ezetimibe decreases liver cholesterol has been in and a diet Turley S.D. G. J.M. of molecular in cholesterol metabolism resulting from cholesterol J. Lipid Res. Scholar). with the a increase in hepatic LDLR in LDL apoB kinetics were not In it was that ezetimibe decreased LDL-cholesterol primarily through reduced VLDL apoB the was not Turley S.D. G. J.M. of molecular in cholesterol metabolism resulting from cholesterol J. Lipid Res. Scholar). with ezetimibe are consistent with of of ezetimibe the in kinetics of and apoB-100 in with primary 2006; Scholar), decreased LDL-cholesterol in patients with primary hypercholesterolemia treated with ezetimibe was due to enhanced LDL apoB clearance. demonstrate that this is due to increased hepatic LDLR expression to hepatic addition of simvastatin enhanced the of ezetimibe by further LDLR and LDL apoB clearance the molecular mechanism for the enhanced decrease in LDL-cholesterol in patients treated with ezetimibe plus a ezetimibe increased hepatic and HMG-CoA reductase expression and J. G. J. Niemann-Pick 1 is the and cholesterol and a of cholesterol J. 2004; Scholar, Turley S.D. G. J.M. of molecular in cholesterol metabolism resulting from cholesterol J. Lipid Res. Scholar), consistent with the increased plasma lathosterol a of cholesterol synthesis. Increased plasma lathosterol has been in patients treated with ezetimibe S. of cholesterol absorption by ezetimibe in humans. Circulation. Scholar). hepatic HMG-CoA reductase expression and cholesterol synthesis has been in H. G. Niemann-Pick 1 protein is for cholesterol 2004; Scholar). increase in cholesterol synthesis the increase in LDLR expression and reductions in plasma that addition of simvastatin increased the expression and of HMG-CoA reductase in liver and of statins is the of a by enhanced of the factor The increased HMG-CoA reductase microsomal J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar). HMG-CoA reductase expression and have been in pigs treated with simvastatin or and the of increase in reductase was to the of cholesterol synthesis in J.R. Barrett M.W. The of decrease in hepatic lipoprotein apolipoprotein B is determined by the of coenzyme A reductase in miniature Scholar). In the addition of simvastatin was to the increase in cholesterol synthesis plasma lathosterol concentrations decreased to with combination A of in the LDL-cholesterol to ezetimibe has been J. J. NPC1L1 is with in plasma low-density lipoprotein to Scholar), and this of the of ezetimibe in some the molecular mechanisms are it is that ezetimibe have greater upregulation of hepatic cholesterol synthesis than patients LDL-cholesterol with of the LDL-cholesterol to ezetimibe for combination with to this LDLR and HMG-CoA reductase expression is primarily regulated by SREBP2 increased significantly in both the liver and of pigs treated with ezetimibe and increased further with the a mechanism for the increased expression of both of The expression of was decreased in and this a for the decrease in hepatic with both the mechanism is hepatic cholesterol NPC1L1 expression was increased in both the and liver by ezetimibe and was increased further by the cholesterol in both consistent with by via the NPC1L1 H. G. Niemann-Pick 1 protein is for cholesterol 2004; Scholar). that expression is regulated to that of for in cholesterol including LDLR and HMG-CoA reductase Y.A. for a and of Scholar). upregulation have increased the of NPC1L1 to ezetimibe for of by the reduction in cholesterol absorption and decrease in plasma phytosterols In to and human liver NPC1L1 H. G. Niemann-Pick 1 protein is for cholesterol 2004; Scholar, Y.A. of NPC1L1 and J. Scholar). expression of NPC1L1 in is than in increased expression was in both The of NPC1L1 in to The of NPC1L1 in a of NPC1L1 in which has been in liver S. J.M. of NPC1L1 to the cholesterol J. 2006; Scholar). and are with to NPC1L1 cholesterol absorption from in the and it is to that it cholesterol from in the in that hepatic including and the efficacy of ezetimibe to the of this mechanism S. J.M. of NPC1L1 to the cholesterol J. 2006; Scholar). In of NPC1L1 by ezetimibe and of cholesterol synthesis by simvastatin in the in reductions in LDL apoB-100 concentrations to monotherapy. Ezetimibe cholesterol absorption and simvastatin the increase in cholesterol synthesis with ezetimibe resulting in a reduction in hepatic cholesterol and a increase in hepatic LDLR expression. apoB was significantly decreased by a reduction in VLDL apoB production and a enhanced LDLR-mediated LDL apoB both of which are to the reduction in hepatic of NPC1L1 by ezetimibe LDL with statins through a mechanism of studies the of recent clinical trials in which enhanced reductions of LDL-cholesterol by ezetimibe with the of patients to LDL-cholesterol was by and from the and of National of and The and for and and of for size with apolipoprotein B cholesteryl ester cholesterol fractional catabolic LDL receptor Niemann-Pick C1-like 1 protein not total cholesterol

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.